This website has been developed by Besins Healthcare (UK) Ltd. This website has separate sections for healthcare professionals and patients who have been prescribed Testogel® 16.2 mg/g gel, within the UK.

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Talking TD with Testogel
Age

Talking TD with

Testogel

(Testosterone) 16.2 mg/g gel

Low mood, depression and weight gain are just some of the symptoms men experience as a result of Testosterone Deficiency (TD). Trust Testogel® to effectively normalise testosterone levels and improve much more than just his libido…1-3

Testogel® 16.2 mg/g gel is indicated in adults as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Let’s start the conversation

Let’s start the conversation…

Talking to a patient about TD can be tough. We’re here to help and have everything you may need to get the conversation started. Learn more about TD, screening & diagnosis.

We are in this together…

We are in this together…

Help your patients get back on track with Testogel® 16.2 mg/g gel. Discover all you and your patients need to know about Testogel® 16.2 mg/g gel.3

Change takes time

Change takes time…

Patients may find it hard to hear that their symptoms won’t improve overnight. Understand what improvement for different symptoms of TD should look like and help set realistic expectations with your patients.4,5

TD has such an impact on
a man’s well-being and
quality of life, it’s time to
challenge the notion that TD is
only about erectile
dysfunction.2

Challenge the TD taboo with us

Challenge the TD
taboo with us

TD can be a difficult topic to broach for both you and your patients. Encouraging your patients to talk to you along their TD journey can make all the difference.5

Support patient self-management with the T Track app

Help your patients to stay on track and feel in control of their Testogel® 16.2 mg/g gel treatment with the T Track app.

T Track app available for both iOS and Android phones.

Support patient self-management with the T Track app

References

  1. Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. Eur Cardiol Rev. 2019;14(2):103–110.
  2. Khera M, Adaikan G, Buvat J, et al. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(12):1787–1804.
  3. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – https://www.medicines.org.uk/emc/product/8919/smpc. Accessed April 2021.
  4. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.
  5. Donatucci C, Cui Z, Fang Y, et al. Long-Term Treatment Patterns of Testosterone Replacement Medications. J Sex Med. 2014;11(8):2092–2099.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com